申请人:Boehringer Ingelheim KG
公开号:US05116971A1
公开(公告)日:1992-05-26
The invention relates to new 1,4-diazepines of the general formula ##STR1## in which R.sub.1, R.sub.2 R.sub.3, X and A have the meaning indicated in the specification. The new compounds are intended for use for the treatment of pathological states and diseases in which PAF (platelet activating factor) is involved.
本发明涉及通式##STR1##的新型1,4-二氮杂环庚烷,其中R1、R2、R3、X和A的含义在说明书中有所指示。这些新型化合物旨在用于治疗涉及血小板活化因子(PAF)的病理状态和疾病。